New hope for advanced lung cancer patients in Real-World treatment study
NCT ID NCT07247227
Summary
This study is observing how well a combination of the immunotherapy drug sugemalimab and standard chemotherapy works for people with advanced non-small cell lung cancer (NSCLC) in real-world medical settings. It aims to see how long the treatment keeps the cancer from getting worse, how long patients live, and how safe the treatment is. The study is for adults with advanced NSCLC who have not yet received systemic treatment for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
cancer hospital， Chinese Academy of medical sciences and Peking union medical college
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.